APYX

Rating neutralAI MemoPost-earnings T+3

Apyx Medical

As of 2026-05-09/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

AYON power-liposuction label expansion remains the clearest discrete upside trigger • 2026-06-30

Expected move: -2%

Biggest risk

At T+3, no clearly confirmed post-May 7 analyst target-change set was surfaced from the checked sources, so the follow-up still reads as a company-reported improvement story rather than a broadly validated Street revision cycle. Risks remain around regulatory timing, OEM decline, tariff/mix pressure, and the need for continued financing flexibility if growth stumbles [#10-Q-2026-05-07] [#10-K-2026-03-10].

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The strongest post-earnings evidence is internal rather than Street-driven: Q1 revenue grew 32.4%, Surgical Aesthetics grew 36.1%, gross margin improved, adjusted EBITDA loss narrowed, and management raised FY2026 revenue guidance to $59.0 million-$60.0 million while citing strong AYON adoption and better-than-expected international demand, including South Korea [#8-K-2026-05-07].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-09

Base target

p=47%

Bull target

p=28%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 raise shifts focus to proving the new FY2026 outlook is repeatable
Full-year execution must offset OEM runoff while preserving liquidity
The strongest post-earnings evidence is internal rather than Street-driven: Q1 revenue grew 32.4%, Surgical Aesthetics grew 36.1%, gross margin improved, adjusted EBITDA loss narrowed, and management raised FY2026 revenue guidance to $59.0 million-$60.0 million while citing strong AYON adoption and better-than-expected international demand, including South Korea [#8-K-2026-05-07].

BearKey bullets

AYON's planned power-liposuction label expansion is still awaiting the anticipated second-quarter 2026 FDA clearance, so a delay would remove a key near-term catalyst [#10-Q-2026-05-07].
Gross margin faces pressure from geographic mix and tariffs that management said began affecting the business in the second half of 2025 [#8-K-2026-05-07].
Liquidity is improved but not de-risked: the company had $31.1 million of cash at March 31, 2026, recurring losses continue, and both the 10-Q and 10-K note dependence on existing cash, product sales, and potentially additional financing [#8-K-2026-05-07] [#10-Q-2026-05-07].

WatchKey bullets

AYON power-liposuction label expansion remains the clearest discrete upside trigger

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $4 (p=47%)

Bull/Bear spread: +25% / -43%

Vs latest close: Bull +25% · Base -2% · Bear -43%

Scenario probabilities

Bull Target: $5 (p=28%)Base Target: $4 (p=47%)Bear Target: $2 (p=25%)

Commentary

Post-earnings tone is modestly constructive but still cautious. The primary company evidence improved on May 7, 2026 through the Q1 release and 10-Q, especially the guidance raise and narrower losses [#8-K-2026-05-07] [#10-Q-2026-05-07]. By May 9, 2026, shares were around $3.67 versus the May 7 anchor close of $3.56, suggesting limited positive follow-through rather than a decisive re-rating. Coverage remains thin, and a clear delayed analyst revision set was not confirmed in checked sources, so this remains a monitored small-cap medtech execution story rather than a fully validated post-earnings upgrade thesis.

As of 2026-05-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 raise shifts focus to proving the new FY2026 outlook is repeatable
Full-year execution must offset OEM runoff while preserving liquidity

Scenarios

Bull Target (Scenario probability)

$5 / p=28% prob

Base Target (Scenario probability)

$4 / p=47% prob

Bear Target (Scenario probability)

$2 / p=25% prob

Price $4 as of 2026-07-07

Nearest Scenario: Base (∆ 2%)

Targets vs latest close: Bull +25% · Base -2% · Bear -43%

Sentiment & Exposure

News Sentiment (30d)

61.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-30
AYON power-liposuction label expansion remains the clearest discrete upside trigger
The company said it submitted a 510(k) in October 2025 to expand AYON to include power liposuction and still anticipates clearance in the second quarter of 2026 [#10-K-2026-03-10] [#10-Q-2026-05-07]. A timely clearance would broaden the platform claim set and could support surgeon adoption; a delay would weaken one of the cleaner forward hooks in the thesis.
Prob 58.00% • Move 22.00% • Priced-in 36.00%

Short-term Catalysts

Next few weeks

Q1 raise shifts focus to proving the new FY2026 outlook is repeatable
2026-06-30
Apyx reported Q1 2026 revenue of $12.5 million, up 32.4% year over year, with Surgical Aesthetics up 36.1% to $10.7 million, gross margin improving to 63.5%, and FY2026 total revenue guidance raised to $59.0 million-$60.0 million from $57.5 million-$58.5 million [#8-K-2026-05-07] [#10-Q-2026-05-07]. The near-term test is whether AYON adoption, international demand, and expense control hold well enough to keep the raise credible rather than looking like a one-quarter step-up.
Prob 62% • Move 16% • Priced-in 48%

Long-term Catalysts

Months to a year

Full-year execution must offset OEM runoff while preserving liquidity
2026-12-31
Management said March 31, 2026 cash was $31.1 million and that, based on AYON uptake, working-capital management, and cost controls, it believes the company can yield cash through 2027 [#8-K-2026-05-07]. That longer-duration view still depends on Surgical Aesthetics growth outpacing the expected OEM decline, while the 10-Q and 10-K continue to frame liquidity, financing availability, and debt obligations as real constraints [#10-Q-2026-05-07] [#10-K-2026-03-10].
Prob 52% • Move 20% • Priced-in 41%

Risks

AYON's planned power-liposuction label expansion is still awaiting the anticipated second-quarter 2026 FDA clearance, so a delay would remove a key near-term catalyst [#10-Q-2026-05-07].
Gross margin faces pressure from geographic mix and tariffs that management said began affecting the business in the second half of 2025 [#8-K-2026-05-07].
Liquidity is improved but not de-risked: the company had $31.1 million of cash at March 31, 2026, recurring losses continue, and both the 10-Q and 10-K note dependence on existing cash, product sales, and potentially additional financing [#8-K-2026-05-07] [#10-Q-2026-05-07].
Management explicitly expects OEM revenue to decline over time, which means Surgical Aesthetics must keep growing fast enough to offset mix drag [#8-K-2026-05-07].
The balance sheet still carries a $37.5 million term loan, and the 10-K highlights the need to maintain sufficient liquidity and meet debt covenants [#10-Q-2026-05-07] [#10-K-2026-03-10].

Peers

Symbol	Summary
BHC	Bausch Health is the closest checked read-through because Apyx's earlier filing-based thesis identifies Solta Medical, owned by Bausch Health, as a notable competitive reference in liposuction/body-contouring workflows, though BHC remains an imperfect and much larger comp.
BSX	Boston Scientific is a broad medtech execution benchmark rather than a direct aesthetics peer; it is mainly useful as a commercialization and margin yardstick versus Apyx's smaller-scale AYON ramp.
EW	Edwards Lifesciences is another loose medtech comparator that highlights the valuation gap between scaled, durable device franchises and Apyx's earlier-stage, more execution-sensitive transition.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-09

AI Stock Memo: APYX - Apyx Medical - RankAlpha